Pharmacologically, both C75 (FASN inhibitor) and TOFA (ACC inhibitor) significantly reduced the lipid droplet levels in the Caki1 and 786O ccRCC cell lines (Fig. S3D). Here, FASN is linked to nonpapillary renal cell carcinoma.